ODM-212 with cancer immunotherapy for advanced solid tumors
Treatments studied
Part of Cancer, Digestive system, Hormones & metabolism, Lungs & breathing clinical trials.
This trial tests a new drug called ODM-212 combined with existing cancer treatments for mesothelioma, pancreatic cancer, or lung cancer with a specific genetic mutation. The study aims to find the right dose and see if adding ODM-212 helps these treatments work better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older and in good enough health to handle cancer treatment (ECOG score 0–1, meaning you can do most daily activities)
- You have advanced cancer that cannot be surgically removed: mesothelioma, pancreatic adenocarcinoma, or lung cancer with a KRAS G12C mutation
- You can swallow pills daily and track whether you take them as instructed
- You have not had chemotherapy or immunotherapy in the past 2 weeks, and any side effects from prior treatments have resolved to mild or better
- You do not have brain metastases (cancer spread to the brain) unless they were treated and cause no symptoms
- You do not have HIV, hepatitis B, or hepatitis C infection
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an experimental drug called ODM-212 for people with advanced solid tumors that have not responded to standard treatments. It may be especially relevant if your tumor has changes in the Hippo pathway (certain genes like NF2 or YAP/TAZ).
This trial tests a new drug (OMTX705) combined with standard chemotherapy (gemcitabine/nab-paclitaxel) and an immunotherapy (tislelizumab) for people with advanced pancreatic cancer. It may be an option if you have had little or no prior chemotherapy.
This trial tests a new drug called ODM-216 in people with advanced cancer that has not responded to standard treatments. The drug is given as a pill (likely), and the study will see how it affects the cancer and what side effects it causes.
This early-phase trial studies OMTX705, given by itself or with an anti–PD-1 immune therapy, in people with advanced solid cancers that can’t be cured or that stopped responding to standard treatments. It aims to check safety and see whether the treatment can shrink tumors or control disease.
This trial tests an experimental oral drug (7HP349) combined with two immunotherapy drugs (ipilimumab and nivolumab) for people with advanced solid tumors. It aims to see if the combination is safe and effective in shrinking tumors.
This trial tests a new drug called BMS-986504 alongside standard treatments for certain advanced cancers (mesothelioma, stomach/esophageal cancer, or bladder cancer). The drug targets a specific genetic change (MTAP deletion) that may make cancer cells more vulnerable to treatment. Joining could help you access a new therapy, but it may not be suitable for everyone.
Hear when a new Mesothelioma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.